Point Of Care Diagnostics Market Overview
\nGlobal Point of Care Diagnostics Market was valued at USD 46.63 billion in 2023 and is expected to reach USD 87.18 billion by the year 2032, at a CAGR of 7.2%.
\nPoint-of-care testing (POCT) is critical for detecting analytes close to the patient, allowing for better disease diagnosis, monitoring, and management. It allows for quick medical decisions because diseases can be diagnosed at an early stage, resulting in better health outcomes for patients by allowing for the early start of treatment. POC testing was first used in 1962 with the development of a method for rapid analysis of blood glucose, and soon after, in 1977, rapid pregnancy tests were developed, ushering in a trend for personalized diagnostics. POC diagnostic devices for monitoring glucose, ECG, blood pressure, and other parameters have greatly aided clinical and personalized healthcare.
\nSeveral prospective POCDs have been developed in recent years, providing a platform for next-generation POCT. The biosensor is the most important component of POCD and is directly responsible for an assay’s bioanalytical performance. Several label-free biosensors, including electrochemical, surface plasmon resonance (SPR), white light reflectance spectroscopy (WLRS), and others, have been developed and are being used to improve POCD. The growing importance of point-of-care diagnostics in environmental monitoring and public health necessitates the incorporation of technologies that enable simple networking, making it easier for healthcare professionals to interpret test results accurately. Thus, in the coming years, remote access integration of POC tests and their networking is expected to open up new avenues for the industry.<\/p>\n
Market Dynamics And Factors For Point of Care Diagnostics Market
\nDrivers:
\nIncreasing Prevalence Of Chronic Diseases
\nThe POCD market is poised for significant growth as the prevalence of chronic diseases such as diabetes, and kidney disease, and as the prevalence of cardiovascular disease rises, necessitating long-term care and frequent monitoring, so will the demand for cost-effective and innovative point-of-care diagnostic products. Chronic diseases are becoming more common all over the world. Changes in societal behaviour, as well as an aging population, are all contributing to a steady rise in these common and costly long-term health issues. As the middle class grows and urbanization accelerates, people are becoming more sedentary. As a result, obesity rates and cases of diseases such as diabetes are increasing. Chronic disease prevalence is expected to rise by 57% by 2020, according to the World Health Organization. As population growth is expected to be greatest in developing countries, emerging markets will be the hardest hit. As a result, the point care diagnostic market is expected to grow during the forecast period.
\nRestraints:
\nAdoption Of Point-Of-Care Diagnostics Is Inadequate
\nThe majority of point-of-care diagnostics tests are performed by clinical professionals with less laboratory experience, such as nurses. Because hospitals have a large number of patients, these individuals concentrate on patient care and are constantly under pressure to provide prompt treatment. The sample collection and all other processes that clinical personnel perform while performing point-of-care diagnostics tests are generally unfamiliar. Furthermore, it has been observed that in most cases, the opinion of lab experts or healthcare workers is ignored. As a result, the decrease in the adoption of point-of-care diagnostics is impeding market growth.
\nOpportunity:
\nTechnological Advancement In POC Diagnostic
\nTechnological advancements have resulted in the development of several novel point-of-care diagnostic devices for a variety of applications. Recent advances in biosensing technology, microfluidics, and paper-based diagnostics will improve diagnostic quality and efficiency. Scientists and entrepreneurs have had a significant impact on the development of next-generation POC diagnostic devices based on cutting-edge technologies such as Artificial Intelligence (AI), the Internet of Things (IoT), and so on. POC technologies combined with smart information and communications technology (ICT) hold great promise for managing resources sustainably and improving healthcare delivery in rural areas. Thus, the future holds a lucrative opportunity for the point care diagnostic market.
\nMarket Dynamics And Factors For Point Care Diagnostics Market
\nBy Application, the glucose monitoring segment is forecasted to dominate the point care diagnostic market in the upcoming future. Glucose monitoring is the most common application for point-of-care diagnostic tests. Diabetes patients are monitored using point-of-care testing (POCT) for glucose at the bedside, at home, or in the hospital. The use of point-of-care (POC) glucose meters in self-monitoring of blood glucose is a valuable tool for managing glycemic control in diabetic patients. In adaptive clinical trials involving dose adjustment and blinded studies, glucose testing at the point of care has been used frequently. The most common tests are glucose and HBA1C. Small blood volumes of whole or venous samples are used in CLIA-Waived and moderately complex platforms. Results will be available in minutes. To eliminate potential preanalytical, analytical, and post-analytical errors, the POCT program for glucose should be evaluated. Thus, consolidating the growth of this segment in the projected timeframe.
\nBy platform, the immunoassays segment is expected to have the highest share of the point of care diagnostic market in the projected timeframe. Immunoassays are valuable tools and the traditional gold standard in infectious disease diagnostics, detecting microbial antigens of pathogen-specific antibodies in crude samples such as blood, saliva, or nasal swabs, saving significant time when compared to culturing approaches, which is a critical bottleneck for in treating patients with severe disease. Enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays (LFIAs), and chemiluminescent immunoassays are the most commonly used immunoassays for infectious disease serological testing (CLIAs). LIFAs are an especially appealing option because they require less operator skill and have the potential to be used in point-of-care settings. Thus, driving the growth of the immunoassays segment.
\nBy end-users, the diagnostic laboratories segment is expected to dominate the point care diagnostic market in the forecasted timeframe. The prevalence of various ailments is increasing the point care diagnostic market in diagnostic laboratories. Because of the increasing number of COVID-19 cases worldwide and the governments of various countries’ repeated requests for people to be tested, many stand-alone diagnostic centers, hospital-based diagnostic labs, and diagnostic chains have been approved and accredited to perform COVID-19 tests. Thus, strengthening the development of this segment.
\nRegional Analysis Of Point of Care Diagnostics Market
\nThe North American region is anticipated to have the highest share of the point of care diagnostic market in the forecast period due to the growing awareness about the diagnosis of diseases. The global POCT market is expected to grow at a compound annual growth rate (CAGR) of 9.8 percent from 2016 to 2021, from US$ 23.16 billion in 2016. North America accounts for the majority of the global POCT market due to high healthcare affordability, premium healthcare infrastructure, and a high level of patient awareness.
\nThe Asia Pacific region is expected to have the second-highest share of the point of care diagnostic market in the projected timeframe. In India, where healthcare resources and infrastructure are distributed unevenly, point-of-care tests are becoming an important tool for increasing diagnostic coverage of the population. India is a developing economy and a popular location for market investments. The development of healthcare infrastructure, combined with an increase in the prevalence of chronic and targeted diseases such as diabetes and cancer, as well as infectious diseases such as HIV, syphilis, COVID-19, RSV, and others, is expected to drive the regional market. Aside from the growing geriatric population, rising stress levels, and increased use of novel immunoassay techniques, strengthening the development of the point-of-care diagnostic market during the forecast period.
\nThe point-of-care diagnostic market in the European region is expected to develop at a significant growth in the projected timeframe. COVID-19 has had a significant impact on Europe, particularly France. As a result of the region’s exponential increase in COVID-19 cases, the European economy is suffering. With a high number of fatalities, Spain, Italy, Germany, France, and the United Kingdom are among the most affected European countries. According to the International Health Regulation, the current coronavirus (COVID-19) outbreak has been declared a Public Health Emergency of International Concern by WHO. The rising number of coronavirus infections and demand for advanced diagnostic solutions present a favorable opportunity for the region’s adoption of point-of-care diagnostic kits. Rising investments and business activities by industry players are also expected to drive the point-of-care diagnostic market during the forecast period.
\nCovid-19 Impact Analysis On Point of Care Diagnostics Market
\nThe COVID-19 pandemic has shifted the POC testing landscape in the world. It has fuelled research into the development of testing strategies that are both quick and inexpensive and can be used as point-of-care testing in the community. The pandemic has hastened the trend of experimenting with decentralization. Reaching out to patients outside of laboratories, hospitals, and homes enables a faster response to clinical needs. Point-of-care (POC) detection technologies that enable decentralized, rapid, sensitive, low-cost COVID-19 infection diagnostics are desperately needed around the world. The field of COVID-19 POC diagnostics is rapidly evolving, with many technologies approved for commercialization in the last ten months. In this Perspective, the current state of POC technologies for COVID-19 infection diagnosis and monitoring, as well as future challenges in COVID-19 diagnostics. As the COVID-19 pandemic becomes endemic, the advances made this year will most likely be used to predict future outbreaks and pandemics.
\nTop Key Players Covered In Point Care Diagnostics Market<\/p>\n
F. Hoffmann-La Roche Ltd (Basel, Switzerland)<\/p>\n
Thermo Fisher Scientific Inc. (Massachusetts, U.S.)<\/p>\n
Abbott Laboratories (Illinois, U.S.)<\/p>\n
Quest Diagnostics Incorporated (New Jersey, U.S.)<\/p>\n
BD (Franklin Lakes, U.S.)<\/p>\n
BioMerieux SA (Marcy l’Etoile, France)<\/p>\n
Cardinal Health, Inc. (Ohio, U.S.)<\/p>\n
Mesa Biotech (California, U.S.)<\/p>\n
Cepheid (California, U.S.)<\/p>\n
Trinity Biotech (Bray, Ireland)<\/p>\n
Quidel Corporation (San Diego, U.S.)<\/p>\n
Bio-Rad Laboratories Inc. (California, U.S.) and Other Major Players.
\nKey Industry Development In The Point Of Care Diagnostics Market
\nIn January 2022, Roche launched its Cobas Pulse System in countries that accept the CE Mark. This is the latest generation of connected point-of-care solutions from Roche Diagnostics for professional blood glucose management.
\nIn February 2021, Mesa Biotech, Inc. a privately held point-of-care molecular diagnostic company, has been acquired by Thermo Fisher Scientific Inc. Mesa Biotech created the Accula System, a point-of-care PCR-based infectious disease testing platform.<\/p>\n","protected":false},"excerpt":{"rendered":"
Point-of-care testing (POCT) is critical for detecting analytes close to the patient, allowing for better disease diagnosis, monitoring, and management. It allows for quick medical decisions because diseases can be diagnosed at an early stage, resulting in better health outcomes for patients by allowing for the early start of treatment.<\/p>\n","protected":false},"featured_media":14100,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[194],"product_tag":[],"class_list":["post-18654","product","type-product","status-publish","has-post-thumbnail","product_cat-healthcare-life-sciences","first","instock","virtual","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n